Clinical trial · Interventional
Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
The Effectivity and Toxicity of Methylsulfonic Apatinib for Extensively Pre-treated Advanced Sarcoma: a Multicentric Retrospective Study in China
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of three Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated sarcoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Efficacy | — | UNRESOLVED | — |
| Toxicity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Methylsulfonic apatinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- osteosarcoma
- description
- all patients had been given apatinib alone
- interventionNames
- Drug: Methylsulfonic apatinib
- type
- EXPERIMENTAL
- label
- Ewing sarcoma
- description
- Some of patients had been given apatinib alone while some of them had been given apatinib+everolimus
- interventionNames
- Drug: Methylsulfonic apatinib
- type
- EXPERIMENTAL
- label
- soft tissue sarcoma
- description
- Some of the patients had been given apatinib alone while some of the patients had been given apatinib together with GT chemotherapy, which was gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 day.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * 1\) histologically confirmed high-grade sarcoma; * 2\) initial treatment in the orthopedic oncology departments of the three affiliated hospitals of Peking University; * 3\) tumors not amenable to curative treatment or inclusion in clinical trials; * 4\) unresectable local advanced lesions or multiple metastatic lesions that could not be cured by local therapy; * 5\) measurable lesions according to Response Evaluation Criteria for Solid Tumors (RECIST1.1) \[8\]; * 6\) Eastern Cooperative Oncology Group performance status 0 or 1 \[9\]; and 7) acceptable hematologic, hepatic, and renal function. Exclusion Criteria: * had been previously exposed to other TKIs; * had central nervous system metastasis; * had other kinds of malignant tumors at the same time; had cardiac insufficiency or arrhythmia; * had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++ and so on; * had pleural or peritoneal effusion that needs to be handled by surgical treatment; * combined with other infections or wounds * were pregnant or breastfeeding.
References
Publications (0)
Data not yet available